2.50
Hdl Handle:
http://hdl.handle.net/2336/2849
Title:
Acute leukaemia in children with Down syndrome: a population-based Nordic study
Authors:
Zeller, Bernward; Gustafsson, Göran; Forestier, Erik; Abrahamsson, Jonas; Clausen, Niels; Heldrup, Jesper; Hovi, Liisa; Jonmundsson, Gudmundur; Lie, Sverre O; Glomstein, Anders; Hasle, Henrik
Citation:
Br. J. Haematol. 2005, 128(6):797-804
Issue Date:
1-Mar-2005
Abstract:
To determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed. Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified. 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS. In ALL, DS patients had similar age and sex distribution and no major differences in blood counts compared with non-DS children. None of the DS patients had T cell leukaemia. Outcome was inferior to that of non-DS children and treatment results did not improve over time. In AML, DS patients showed a significant female predominance and all but one were <5 years old. DS patients with AML had significantly lower platelet and white blood cell counts and two-thirds were type M7 as according to the French-American-British classification. None of the patients <5 years of age had typical AML cytogenetic aberrations. Outcome was far better in the DS group. DS patients treated for AML after 1992 had an excellent outcome (probability of event-free survival, 83 +/- 6%). The high proportion of female DS patients with AML is unexplained. The differing treatment results in AML versus ALL need further evaluation and represent a challenge for the coming years.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.blackwell-synergy.com/doi/full/10.1111/j.1365-2141.2005.05398.x

Full metadata record

DC FieldValue Language
dc.contributor.authorZeller, Bernward-
dc.contributor.authorGustafsson, Göran-
dc.contributor.authorForestier, Erik-
dc.contributor.authorAbrahamsson, Jonas-
dc.contributor.authorClausen, Niels-
dc.contributor.authorHeldrup, Jesper-
dc.contributor.authorHovi, Liisa-
dc.contributor.authorJonmundsson, Gudmundur-
dc.contributor.authorLie, Sverre O-
dc.contributor.authorGlomstein, Anders-
dc.contributor.authorHasle, Henrik-
dc.date.accessioned2006-05-18T14:31:38Z-
dc.date.available2006-05-18T14:31:38Z-
dc.date.issued2005-03-01-
dc.identifier.citationBr. J. Haematol. 2005, 128(6):797-804en
dc.identifier.issn0007-1048-
dc.identifier.pmid15755283-
dc.identifier.doi10.1111/j.1365-2141.2005.05398.x-
dc.identifier.otherPED12en
dc.identifier.urihttp://hdl.handle.net/2336/2849-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractTo determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed. Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified. 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS. In ALL, DS patients had similar age and sex distribution and no major differences in blood counts compared with non-DS children. None of the DS patients had T cell leukaemia. Outcome was inferior to that of non-DS children and treatment results did not improve over time. In AML, DS patients showed a significant female predominance and all but one were <5 years old. DS patients with AML had significantly lower platelet and white blood cell counts and two-thirds were type M7 as according to the French-American-British classification. None of the patients <5 years of age had typical AML cytogenetic aberrations. Outcome was far better in the DS group. DS patients treated for AML after 1992 had an excellent outcome (probability of event-free survival, 83 +/- 6%). The high proportion of female DS patients with AML is unexplained. The differing treatment results in AML versus ALL need further evaluation and represent a challenge for the coming years.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://www.blackwell-synergy.com/doi/full/10.1111/j.1365-2141.2005.05398.xen
dc.subjectAcute Diseaseen
dc.subjectAge Distributionen
dc.subjectChilden
dc.subjectDisease-Free Survivalen
dc.subjectDown Syndromeen
dc.subjectInfanten
dc.subjectLeukemia, Lymphocytic, Acute, L1en
dc.subjectLeukemia, Myeloiden
dc.subjectNorway/epidemiologyen
dc.titleAcute leukaemia in children with Down syndrome: a population-based Nordic studyen
dc.typeArticleen
dc.identifier.journalBritish journal of haematologyen
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.